Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treprostinil in Intermediate-risk PAH
NCT07177703Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by Zhongshan Hospital, Fudan University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07177703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177703.